References
- Adams CP, Brantner VV. (2006). Estimating the cost of new drug development: is it really $802 million? Hlth Affair 25:420–8.
- Bemis GW, Murcko MA. (1996). The properties of known drugs. 1. Molecular frameworks. J Med Chem 39:2887–93.
- Bewick V, Cheek L, Ball J. (2004). Statistics review 13: Receiver operating characteristic curves. Crit Care 8:508–12.
- Davies B, Morris T. (1993). Physiological parameters in laboratory animals and humans. Pharm Res 10:1093–5.
- Ekins S, Waller CL, Swaan PW, Cruciani G, Wrighton SA, Wikel JH. (2000). Progress in predicting human ADME parameters in silico. J Pharmacol Toxicol Meth 44:251–72.
- Evans CA, Jolivette LJ, Nagilla R, Ward KW. (2006). Extrapolation of preclinical pharmacokinetics and molecular feature analysis of ‘discovery-like’ molecules to predict human pharmacokinetics. Drug Metab Dispos 34:1255–65.
- Fawcett T. (2006). An introduction to ROC analysis. Patt Recogn Lett 27:861–74.
- Fox T, Kriegl JM. (2006). Machine learning techniques for in silico modeling of drug metabolism. Curr Top Med Chem 6:1579–92.
- Ito K, Houston BJ. (2004). Comparison of the use of liver models for predicting drug clearance using in vitro kinetic data from hepatic microsomes and isolated hepatocytes. Pharm Res 22:785–92.
- Kola I, Landis J. (2004). Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3:711–15.
- McIntyre TA, Han C, Xiang H, Bambal B, Davis CB. (2008). Differences in the total body clearance of lead compounds in the rat and mouse: impact on PK screening strategy. Xenobiotica 38:605–19.
- Nagilla R, Frank KA, Jolivette LJ, Ward KW. 2006. Investigation of the utility of published in vitro intrinsic clearance data for the prediction of in vivo clearance. J Pharmacol Toxicol Meth 53:106–16.
- Obach RS, Lombardo F, Waters NJ. (2008). Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug Metab Dispos 36: 1385–405.
- Rogers D, Brown RD, Hahn M. (2005). Using extended- connectivity fingerprints with Laplacian-modified Bayesian analysis in high-throughput screening follow-up. J Biomol Screen 10:682–6.
- Sciabola S, Carosati E, Curcurull-Sanchez L, Baroni M, Manhold R. (2007). Novel TOPP descriptors in 3D-QSAR analysis of apoptosis inducing 4-aryl-4H-chromenes: Comparison versus other 2D- and 3D-descriptors. Bioorg Med Chem 15:6450–62.
- Shiran MR, Proctor MJ, Howgate EM, Rowland-Yeo K, Tucker GT, Rostami-Hodjegan A. (2006). Prediction of metabolic drug clearance in humans: In vitro–in vivo extrapolation versus allometric scaling. Xenobiotica 36:567–80.
- Tang H, Hussein A, Leal M, Mayersohn M, Fluhler E. (2007). Interspecies prediction of human drug clearance based on scaling data from one or two animal species. Drug Metab Dispos 35:1886–93.
- Ward KW, Smith BR. (2004). A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog and monkey to humans. I. Clearance. Drug Metab Dispos 32:603–11.
- Webb AR. (2002). Statistical pattern recognition, 2nd ed. New York, NY: Wiley.
- Wishart DS. (2007). Improving early drug discovery through ADME modeling: an overview. Drugs R D 8:349–362.
- Xia X, Maliski EG, Gallant P, Rogers D. (2004). Classification of kinase inhibitors using a Bayesian model. J Med Chem 47:4463–70.
- Xiang H, McSurdy-Freed J, Moorthy GS, Hugger E, Bambal R, Han C, Ferrer S, Gargallo D, Davis CB. (2006). Preclinical drug metabolism and pharmacokinetic evaluation of GW844520, a novel anti-malarial mitochondrial electron transport inhibitor. J Pharm Sci 95:2657–72.
- Zhou D, Aleyunas Y, Liu R. (2008). Scores of extended connectivity fingerprint as descriptors in QSPR study of melting point and aqueous solubility. J Chem Inf Model 48:981–7.